A new era of neurotoxin treatment is coming soon to Canada - offering a new option for patients curious about facial injectables, but who may be hesitant to commit to longer-lasting results.

From the makers of BOTOX COSMETIC^®, meet Boey^®.

Boey^® is the first and only rapid onset,
short duration neurotoxin for frown lines.¹

As the first true new serotype in over 20 years, Boey^® offers:

Boey^® offers a new way to take that first step.

Be among the first to learn more about the launch of Boey^® and discover how this innovative new treatment is changing what’s possible in neurotoxin care.
More exciting details are coming soon.

You received this email because you signed up to receive communications from Allergan Aesthetics, and AbbVie Corporation division (“AbbVie”). If you no longer wish to receive communications from Allergan Aesthetics, you may withdraw your consent at any time by emailing MKH-Customer-OptOut@allergan.com.

This product may not be available to all healthcare providers. Availability depends on your province and scope of practice, and purchase requires confirmation of applicable authorization.

Allergan Aesthetics, an AbbVie company,
1380 Rodick Rd. Suite 300, Markham, ON L3R 4G5
© 2026 AbbVie. All rights reserved.

† Boey^® is the first botulinum neurotoxin approved in aesthetics based on botulinum neurotoxin type E.
It has a distinct pharmacologic profile, with onset of effect observed within hours after injection and a duration of response that lasted approximately 2–3 weeks. Due to its early onset of effect and short duration, Boey^® should be used occasionally. No other aesthetic neurotoxin with this clinical profile has previously been approved.^1,2

1. BOEY^® Product Monograph. Date of Authorization: June 30, 2026.
2. Lain et al., Rapid Results With TrenibotulinumtoxinE for the Treatment of Glabellar Lines
in Toxin-Naive Adults: Safety, Efficacy, and Satisfaction Findings From a Pivotal Phase 3
Study, Aesthetic Surgery Journal, 2026.

CA-TRENI-260028

www.allerganaesthetics.ca